AZN
Price
$80.21
Change
+$0.31 (+0.39%)
Updated
Sep 2, 04:59 PM (EDT)
Capitalization
247.21B
65 days until earnings call
NVS
Price
$126.63
Change
+$0.08 (+0.06%)
Updated
Sep 2, 04:59 PM (EDT)
Capitalization
244.29B
56 days until earnings call
Interact to see
Advertisement

AZN vs NVS

Header iconAZN vs NVS Comparison
Open Charts AZN vs NVSBanner chart's image
AstraZeneca
Price$80.21
Change+$0.31 (+0.39%)
Volume$101.19K
Capitalization247.21B
Novartis AG
Price$126.63
Change+$0.08 (+0.06%)
Volume$17.09K
Capitalization244.29B
AZN vs NVS Comparison Chart in %
Loading...
AZN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AZN vs. NVS commentary
Sep 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZN is a Buy and NVS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 03, 2025
Stock price -- (AZN: $79.90 vs. NVS: $126.55)
Brand notoriety: AZN: Notable vs. NVS: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AZN: 62% vs. NVS: 47%
Market capitalization -- AZN: $247.21B vs. NVS: $244.29B
AZN [@Pharmaceuticals: Major] is valued at $247.21B. NVS’s [@Pharmaceuticals: Major] market capitalization is $244.29B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $656.73B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $89.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AZN’s FA Score shows that 1 FA rating(s) are green whileNVS’s FA Score has 3 green FA rating(s).

  • AZN’s FA Score: 1 green, 4 red.
  • NVS’s FA Score: 3 green, 2 red.
According to our system of comparison, NVS is a better buy in the long-term than AZN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AZN’s TA Score shows that 3 TA indicator(s) are bullish while NVS’s TA Score has 6 bullish TA indicator(s).

  • AZN’s TA Score: 3 bullish, 5 bearish.
  • NVS’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, NVS is a better buy in the short-term than AZN.

Price Growth

AZN (@Pharmaceuticals: Major) experienced а -1.32% price change this week, while NVS (@Pharmaceuticals: Major) price change was -0.34% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.29%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was +10.10%.

Reported Earning Dates

AZN is expected to report earnings on Nov 06, 2025.

NVS is expected to report earnings on Oct 28, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+0.29% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AZN($247B) and NVS($244B) have the same market capitalization . AZN has higher P/E ratio than NVS: AZN (30.09) vs NVS (18.45). NVS YTD gains are higher at: 34.730 vs. AZN (24.550). NVS has higher annual earnings (EBITDA): 22.7B vs. AZN (16.8B). AZN (7.11B) and NVS (7B) have equal amount of cash in the bank . NVS (32.6B) and AZN (32.8B) have identical debt. AZN (56.5B) and NVS (55.2B) have equivalent revenues.
AZNNVSAZN / NVS
Capitalization247B244B101%
EBITDA16.8B22.7B74%
Gain YTD24.55034.73071%
P/E Ratio30.0918.45163%
Revenue56.5B55.2B102%
Total Cash7.11B7B102%
Total Debt32.8B32.6B101%
FUNDAMENTALS RATINGS
AZN vs NVS: Fundamental Ratings
AZN
NVS
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
24
Undervalued
14
Undervalued
PROFIT vs RISK RATING
1..100
3713
SMR RATING
1..100
4629
PRICE GROWTH RATING
1..100
5247
P/E GROWTH RATING
1..100
8582
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVS's Valuation (14) in the Pharmaceuticals Major industry is in the same range as AZN (24). This means that NVS’s stock grew similarly to AZN’s over the last 12 months.

NVS's Profit vs Risk Rating (13) in the Pharmaceuticals Major industry is in the same range as AZN (37). This means that NVS’s stock grew similarly to AZN’s over the last 12 months.

NVS's SMR Rating (29) in the Pharmaceuticals Major industry is in the same range as AZN (46). This means that NVS’s stock grew similarly to AZN’s over the last 12 months.

NVS's Price Growth Rating (47) in the Pharmaceuticals Major industry is in the same range as AZN (52). This means that NVS’s stock grew similarly to AZN’s over the last 12 months.

NVS's P/E Growth Rating (82) in the Pharmaceuticals Major industry is in the same range as AZN (85). This means that NVS’s stock grew similarly to AZN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AZNNVS
RSI
ODDS (%)
Bearish Trend 5 days ago
44%
Bearish Trend 5 days ago
50%
Stochastic
ODDS (%)
Bearish Trend 5 days ago
43%
Bearish Trend 5 days ago
52%
Momentum
ODDS (%)
N/A
Bullish Trend 5 days ago
55%
MACD
ODDS (%)
Bearish Trend 5 days ago
50%
Bullish Trend 5 days ago
55%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
44%
Bearish Trend 5 days ago
44%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
55%
Bullish Trend 5 days ago
46%
Advances
ODDS (%)
Bullish Trend 14 days ago
54%
Bullish Trend 7 days ago
49%
Declines
ODDS (%)
Bearish Trend 26 days ago
44%
Bearish Trend 28 days ago
45%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
48%
Bearish Trend 5 days ago
42%
Aroon
ODDS (%)
Bullish Trend 5 days ago
52%
Bullish Trend 5 days ago
41%
View a ticker or compare two or three
Interact to see
Advertisement
AZN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PNFP97.220.39
+0.40%
Pinnacle Financial Partners
VRDN18.38-0.06
-0.33%
Viridian Therapeutics
CITY.X1.002995-0.014491
-1.42%
Manchester City Fan Token cryptocurrency
DSGN5.53-0.11
-1.95%
Design Therapeutics
BTCM2.81-0.07
-2.43%
BIT Mining Limited

AZN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AZN has been loosely correlated with GSK. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if AZN jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AZN
1D Price
Change %
AZN100%
-0.11%
GSK - AZN
62%
Loosely correlated
+0.58%
NVS - AZN
61%
Loosely correlated
+0.06%
SNY - AZN
49%
Loosely correlated
-0.92%
PFE - AZN
45%
Loosely correlated
+0.65%
LLY - AZN
41%
Loosely correlated
+0.08%
More

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been closely correlated with GSK. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
+0.06%
GSK - NVS
68%
Closely correlated
+0.58%
AZN - NVS
61%
Loosely correlated
-0.11%
PFE - NVS
57%
Loosely correlated
+0.65%
JNJ - NVS
55%
Loosely correlated
+0.98%
SNY - NVS
48%
Loosely correlated
-0.92%
More